No abstract

clinicaltrials.gov Identifier: NCT01645202.

In the present trial, characterized by low event rates, we did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation. However, the results of the trial must be considered in view of its premature termination and lower than expected event rates. The trial is registered with ClinicalTrials.gov, Identifier: NCT00661206.

The occurrence of significant AR after TAVI can be predicted by anatomic and procedural variables. A model such as that presented can be used to select suitable patients for this procedure and guide operators during implantation of the device.

Unique identifier NCT00976092 (www.clinicaltrials.gov).

Background-In ST-segment elevation myocardial infarction, a troponin T Ն0.1 g/L on admission indicates poorer prognosis despite early reperfusion. To evaluate the underlying reason, we studied the value of cardiac troponin T (cTnT) for prediction of outcomes, epicardial blood flow, and myocardial reperfusion after primary percutaneous intervention. Methods and Results-Patients (nϭ140) admitted within 12 hours after onset of symptoms were stratified by admission cTnT. Epicardial and myocardial reperfusion were graded by the TIMI score and by measurement of relative increases of myoglobin, cTnT, and creatine kinase (CK)-MB 60 minutes after recanalization, respectively. cTnT was positive in 64 patients (45.7%) and was associated with longer median time intervals to admission (5.5 versus 3.5 hours, PϽ0.001) and higher mortality rates after 30 days (12.5% versus 3.9%, Pϭ0.06) and 9 months (14% versus 3.9%, Pϭ0.005). cTnT independently predicted a 3.2-fold risk for incomplete epicardial reperfusion (Pϭ0.03). In addition, cTnT Ն0.1 g/L was associated with more severely impaired myocardial perfusion despite normal epicardial flow, as indicated by lower 60-minute ratios of myoglobin (2.6 versus 7.6, Pϭ0.007), cTnT (6.6 versus 29.2, PϽ0.001), and CK-MB (3.5 versus 21.4, Pϭ0.002) and a tendency for less resolution of ST-segment elevations (54% versus 60%, Pϭ0.08). Conclusions-cTnT

Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.

No abstract